57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia

Gastroesophageal Reflux Disease (GERD): Pathophysiology, Clinical Presentation & Initial Therapy

Gastroesophageal reflux disease (GERD) is defined as the retrograde flow of gastroduodenal contents into the esophagus, producing troublesome symptoms and/or mucosal complications. Affecting approximately 20% of the adult population in North America, GERD represents one of the most frequent primary care presentations. Understanding its underlying mechanics, distinguishing typical from atypical presentations, and executing evidence-based management are core family medicine competencies.

Pathophysiologic Mechanisms

The antireflux barrier at the gastroesophageal junction (GEJ) depends on the anatomical alignment and functional integrity of the intrinsic lower esophageal sphincter (LES) smooth muscle and the extrinsic crural diaphragm:

• Transient Lower Esophageal Sphincter Relaxations (TLESRs):
  • The predominant pathophysiologic mechanism in patients with mild-to-moderate, non-erosive GERD.
  • TLESRs are physiologic, vasovagal reflexes triggered by gastric fundic distention that allow swallowed air to vent (physiologic belching). In GERD, TLESRs occur with increased frequency, last longer (often >10 to 35 seconds), and are more frequently accompanied by retrograde acid and pepsin reflux.
• Hypotensive Lower Esophageal Sphincter:
  • Abnormally low basal LES resting pressure (<10 to 15 mmHg; normal is 15 to 30 mmHg).
  • Allows free "stress reflux" during acute elevations in intra-abdominal pressure (e.g., coughing, straining, bending forward).
• Hiatal Hernia (Type I Axial / Sliding Hernia):
  • Migration of the GEJ and gastric cardia through the esophageal diaphragmatic hiatus into the posterior mediastinum.
  • Disrupts the normal high-pressure zone by dissociating the intrinsic LES from the extrinsic diaphragmatic pinchcock mechanism. The herniated gastric pouch serves as an acidic reservoir that easily refluxes during swallowing and delays esophageal acid clearance.
• Impaired Esophageal Clearance & Acid Buffering:
  • Defective secondary peristalsis fails to strip refluxed liquid back into the stomach.
  • Decreased salivary production (saliva contains bicarbonate and epidermal growth factor) diminishes chemical neutralization of luminal acid.
• Delayed Gastric Emptying (Gastroparesis):
  • Elevated intragastric volume increases postprandial wall tension, stimulating excessive TLESRs and promoting acid overflow.
• The Gastric "Acid Pocket":
  • A unbuffered pool of highly acidic (pH 1.5 to 2.0) gastric juice that forms on top of chyme in the gastric fundus immediately after eating, directly positioned at the vulnerable GEJ.

Clinical Presentation: Typical vs. Extraesophageal Symptoms

                      CLINICAL SPECTRUM OF GERD SYMPTOMS

   Category             Signs and Symptoms & Pathophysiology
   ═════════════════════════════════════════════════════════════════════════════
   Typical Symptoms     • Heartburn (pyrosis): Substernal burning discomfort
                          radiating upward toward the neck, exacerbated by meals,
                          bending over, or lying supine
                        • Acid Regurgitation: Effortless return of sour, bitter
                          gastric contents into the pharynx or mouth
                        • Water Brash: Sudden reflex salivation induced by acid
                          irritation of the lower esophageal mucosa

   Atypical /           • Chronic Cough: Secondary to vagally mediated esophageal-
   Extraesophageal        bronchial neural reflex or microaspiration into larynx
   Symptoms             • Adult-Onset Asthma / Nocturnal Wheezing: Reflex
                          bronchospasm triggered by acid fumes
                        • Reflux Laryngitis: Morning hoarseness, throat clearing,
                          posterior laryngitis (arytenoid erythema/edema)
                        • Globus Sensation: Persistent feeling of a lump or fullness
                          in the throat unrelated to swallowing
                        • Dental Erosions: Acid dissolution of lingual and palatal
                          enamel surfaces (often identified by dentists)
                        • Non-Cardiac Chest Pain: Squeezing retrosternal pain
                          mimicking acute coronary syndrome; requires cardiac
                          clearance before attributing exclusively to GERD
   ═════════════════════════════════════════════════════════════════════════════

Lifestyle Interventions: Evidence-Based Recommendations

Non-pharmacologic lifestyle interventions constitute the essential foundation of GERD management and should be instituted in every patient:

1. Weight Loss: The single lifestyle intervention with the strongest evidence (Grade A recommendation). Increased central and visceral adiposity elevates intra-abdominal pressure, widens the gastroesophageal pressure gradient, and increases hiatal hernia formation. Weight loss consistently improves esophageal pH profiles and leads to complete resolution of symptoms in up to 40% of overweight or obese individuals.
2. Head-of-the-Bed Elevation (6 to 8 inches): Elevating the head of the bed using 6- to 8-inch solid bed risers under the headboard posts or sleeping on a firm medical wedge pillow utilizes gravity to accelerate nocturnal acid clearance and prevent proximal reflux. Clinical Pearl: Stacking multiple standard bed pillows is completely ineffective and counterproductive, as it flexes the neck and waist, increasing intra-abdominal pressure.
3. Avoid Late-Night Meals: Refraining from food and caloric liquids for at least 2 to 3 hours before lying recumbent ensures substantial gastric emptying prior to sleep, eliminating the recumbent postprandial acid pocket.
4. Left Lateral Decubitus Positioning: Sleeping on the left side positions the GEJ above the level of gastric contents, decreasing nocturnal reflux events compared to right lateral or prone positioning.
5. Dietary Modification: While evidence for universal dietary restriction is variable, patients should identify and eliminate personal triggers that relax the LES (chocolate, peppermint, caffeine, alcohol, high-fat meals) or cause direct mucosal irritation (citrus, tomato-based sauces, spicy foods, carbonated beverages).
6. Tobacco and Alcohol Cessation: Nicotine and ethanol directly reduce basal LES tone, impair salivary secretion, and blunt esophageal clearance.

First-Line Pharmacotherapy: Empiric PPI Trial

In patients presenting with typical GERD symptoms (heartburn and regurgitation) without alarm features, clinical practice guidelines from the American College of Gastroenterology (ACG) and American Gastroenterological Association (AGA) recommend an empiric 8-week trial of once-daily Proton Pump Inhibitor (PPI) therapy:

• First-Line Agents and Standard Dosages:
  • Omeprazole 20 to 40 mg PO once daily
  • Pantoprazole 40 mg PO once daily
  • Esomeprazole 20 to 40 mg PO once daily
  • Lansoprazole 30 mg PO once daily
• Crucial Administration Timing Rule:
  • PPIs are prodrugs requiring an acidic environment for bioactivation inside the secretory canaliculus of the gastric parietal cell. Once activated, they form a covalent disulfide bond with the active $H^+/K^+$ ATPase pump, irreversibly inhibiting acid secretion.
  • Parietal cell proton pumps are newly synthesized and inserted into the luminal membrane primarily in response to food stimulation.
  • Therefore, PPIs MUST be ingested 30 to 60 minutes before the first meal of the day (typically breakfast) to ensure peak circulating systemic drug concentrations coincide exactly with maximal parietal cell stimulation. Taking a PPI at bedtime, with a meal, or on an empty stomach without subsequent food reduces clinical efficacy by 50% or more.
• Therapeutic Escalation:
  • If symptoms show an incomplete response after 4 to 8 weeks of once-daily therapy, the dosage should be optimized to twice-daily PPI therapy (taken 30 to 60 minutes before breakfast and 30 to 60 minutes before dinner).

Indications for Upper Endoscopy, Alarm Features & PPI Safety Counseling

While empiric PPI therapy is appropriate for uncomplicated typical GERD, indiscriminate PPI prescribing without structural evaluation can delay the detection of esophageal adenocarcinoma, peptic strictures, or severe ulceration.

Alarm Features Requiring Prompt Upper Endoscopy (EGD)

The presence of any alarm feature at any age mandates prompt referral for diagnostic esophagogastroduodenoscopy (EGD) with biopsies:

• Dysphagia (Difficulty Swallowing): Particularly progressive dysphagia (solids progressing to liquids), which strongly suggests mechanical obstruction from a peptic stricture, esophageal web/ring, or esophageal carcinoma. Intermittent dysphagia to both solids and liquids suggests an esophageal motility disorder (achalasia) or eosinophilic esophagitis.
• Odynophagia (Painful Swallowing): Strongly suggests deep mucosal ulceration, severe infectious esophagitis (Candida, CMV, HSV), or pill-induced esophagitis (doxycycline, NSAIDs, bisphosphonates, potassium chloride).
• Unintentional Weight Loss: Suggests advanced gastrointestinal malignancy or severe malnutrition.
• Overt Gastrointestinal Bleeding: Hematemesis (bright red blood or "coffee-ground" emesis) or melena.
• Iron Deficiency Anemia: Unexplained microcytic anemia warrants bi-directional endoscopy (EGD and colonoscopy) to rule out occult GI malignancy or Cameron lesions (ulcerations within a large hiatal hernia).
• Persistent Refractory Vomiting: Protracted emesis causing dehydration or electrolyte disturbances.
• Palpable Epigastric Mass or Lymphadenopathy: (e.g., Virchow node [left supraclavicular] or Sister Mary Joseph nodule [periumbilical]).

                      SUMMARY OF EGD INDICATIONS IN GERD

   Clinical Scenario                              Endoscopic Recommendation
   ═════════════════════════════════════════════════════════════════════════════════
   Presence of Alarm Features (any age)           Prompt diagnostic EGD with biopsies

   Refractory Typical Symptoms                    EGD indicated after failure of an 8-week
                                                  trial of optimized twice-daily PPI therapy

   Screening for Barrett's Esophagus              Men with chronic GERD (>5 yrs) and >=2 risk
                                                  factors (age >=50, Caucasian, central obesity,
                                                  smoking, family history)

   Severe Erosive Esophagitis (LA Grade C or D)   Repeat EGD in 8 to 12 weeks after high-dose
                                                  PPI to confirm healing and exclude occult BE
   ═════════════════════════════════════════════════════════════════════════════════

Long-Term PPI Safety: Evidence-Based Counseling

Proton pump inhibitors are among the most widely prescribed drug classes globally. Although highly effective and generally well-tolerated, chronic long-term hypochlorhydria has been linked in large observational cohorts to several potential adverse outcomes. Family physicians must provide balanced, evidence-grounded risk communication:

• Bone Mineral Density Loss and Fragility Fractures:
  • Gastric acidity is essential for the ionization and solubilization of insoluble dietary calcium carbonate. Chronic hypochlorhydria impairs active calcium absorption, triggering secondary hyperparathyroidism and accelerated bone resorption.
  • The FDA issued a safety warning regarding an increased risk of osteoporotic hip, wrist, and spine fractures with high-dose or long-term (>1 year) PPI use. In patients requiring prolonged PPIs who need calcium supplementation, recommend calcium citrate, which does not require gastric acidity for absorption.
• Enteric Infections & Clostridioides difficile Colitis:
  • Gastric acid serves as a formidable physiologic barrier against ingested bacterial pathogens. Suppression of gastric acidity enables vegetative spores and bacteria to survive transit into the lower bowel.
  • PPI use is associated with a 1.5- to 2.5-fold increased risk of Clostridioides difficile-associated diarrhea, as well as increased susceptibility to Campylobacter, Salmonella, and traveler's diarrhea.
• Hypomagnesemia:
  • Prolonged PPI therapy (>1 year) can impair active intestinal magnesium absorption mediated by transient receptor potential melastatin-6 and -7 (TRPM6/TRPM7) ion channels in the enterocyte brush border.
  • Can present with severe tetany, tremor, refractory hypokalemia, and secondary hypocalcemia (impaired PTH release). Baseline and periodic serum magnesium monitoring is prudent in patients on concurrent diuretics or digoxin.
• Vitamin B12 (Cobalamin) Deficiency:
  • Gastric acid and pepsin are mandatory to cleave dietary vitamin B12 from animal salivary haptocorrins and food proteins before it can bind gastric intrinsic factor. Long-term PPI use (>2 to 3 years) can lead to subclinical B12 malabsorption and macrocytic anemia/neuropathy, particularly in elderly or malnourished patients.
• Acute Interstitial Nephritis (AIN) & Chronic Kidney Disease (CKD):
  • Rare, idiosyncratic, immune-mediated hypersensitivity reaction presenting with progressive azotemia, eosinophiluria, and sterile pyuria. PPIs must be discontinued immediately if drug-induced AIN is suspected.

Structured PPI Deprescribing Protocol

Routine continuation of PPI therapy without ongoing clinical indication is widespread. Clinicians should conduct annual deprescribing reviews. Except in patients with definitive indications for indefinite therapy (e.g., Los Angeles Grade C/D severe erosive esophagitis, Barrett's esophagus, peptic esophageal stricture, or high GI bleed risk on chronic dual antithrombotics/NSAIDs), deprescribing should be actively pursued:

1. Preventing Rebound Acid Hypersecretion:
   • Chronic PPI therapy elevates serum gastrin (hypergastrinemia due to lack of negative feedback inhibition by luminal acid). Hypergastrinemia causes ECL cell hyperplasia and parietal cell hypertrophy.
   • Abrupt cessation triggers severe rebound acid hypersecretion, producing intense burning symptoms that patients misinterpret as returning underlying disease, leading to drug resumption.
2. Tapering Regimen:
   • Step 1: Halve the daily dose for 2 to 4 weeks (e.g., reduce omeprazole from 40 mg daily to 20 mg daily, or switch twice-daily to once-daily).
   • Step 2: Space to alternate-day dosing (every other day) for 2 weeks.
   • Step 3: Step-down to an H2-receptor antagonist (famotidine 20 mg once to twice daily) or provide on-demand, as-needed PPI/antacid therapy for breakthrough symptoms.

Barrett's Esophagus: Pathogenesis, ACG 2022 Screening & Surveillance Guidelines

Barrett's esophagus (BE) represents a premalignant metaplastic complication of chronic gastroesophageal reflux disease, characterized by the replacement of the normal stratified squamous epithelium of the distal esophagus with specialized columnar epithelium containing intestinal goblet cells.

Pathogenesis & Risk Stratification

Repetitive mucosal acid and bile acid injury damages the squamous lining, triggering an abnormal, reprogrammed stem cell repair process. Columnar cells with alcian blue-positive goblet cells (specialized intestinal metaplasia) are more resistant to acid erosion but carry an inherent genomic instability that can sequentially progress to low-grade dysplasia (LGD), high-grade dysplasia (HGD), and invasive esophageal adenocarcinoma (EAC). Adenocarcinoma of the esophagus has had the fastest-rising incidence among solid malignancies in Western nations over the last four decades.

                  RISK FACTORS FOR BARRETT'S ESOPHAGUS

   Major Risk Factors                   Clinical Significance
   ═════════════════════════════════════════════════════════════════════════════
   Chronic GERD Duration                Symptoms lasting > 5 years significantly
                                        elevates metaplastic transformation risk
   Male Sex                             3:1 to 4:1 male-to-female predominance
   Age >= 50 Years                      Incidence peaks in the 6th and 7th decades
   Caucasian Race                       Markedly higher prevalence than Black or Hispanic
   Central / Visceral Obesity           Waist-to-hip ratio correlates more strongly
                                        than overall BMI with BE and EAC risk
   Tobacco Smoking History              Significant independent risk factor for EAC
   Family History                       First-degree relative with BE or esophageal
                                        adenocarcinoma doubles to triples individual risk
   ═════════════════════════════════════════════════════════════════════════════

ACG 2022 Screening Recommendations

The American College of Gastroenterology (ACG) recommends a single screening EGD in men with chronic GERD symptoms (>5 years) who have at least TWO additional risk factors: age >=50 years, Caucasian race, central obesity (waist circumference >102 cm), history of cigarette smoking, or a confirmed family history of BE or EAC in a first-degree relative.

• Routine screening in women is NOT recommended due to a very low absolute incidence of EAC, but can be considered if a woman has chronic GERD plus multiple high-risk features.
• If a screening EGD is entirely negative for Barrett's esophagus, routine repeat screening is not indicated.

Endoscopic Staging: The Prague Criteria

During endoscopy, the extent of Barrett's esophagus must be rigorously documented using the standardized Prague C & M Criteria:

• C Value (Circumferential extent): The length (in centimeters) of the circumferential columnar metaplasia above the gastroesophageal junction.
• M Value (Maximal extent): The total length (in centimeters) of the maximal tongue or projection of columnar metaplasia above the GEJ.
• Example: A Barrett segment extending circumferentially for 2 cm with a tongue extending to 5 cm is staged as Prague C2M5.
• "Short-segment" BE is defined as maximal length <3 cm; "long-segment" BE is >=3 cm. Long-segment BE carries a substantially higher rate of neoplastic progression.

ACG 2022 Surveillance & Treatment Guidelines

Tissue biopsies must follow the standardized Seattle Biopsy Protocol: 4-quadrant mucosal biopsies taken every 1 to 2 cm throughout the entire length of the Barrett segment, plus targeted biopsies of any visible mucosal irregularities, plaques, or ulcerations.

                 ACG 2022 BARRETT'S ESOPHAGUS SURVEILLANCE & THERAPY

   Histologic Staging         Annual EAC Risk    Evidence-Based Management Pathway
   ═════════════════════════════════════════════════════════════════════════════════════════════
   Non-Dysplastic             0.1% to 0.3% / yr  Surveillance EGD with 4-quadrant biopsies
   Barrett's Esophagus (NDBE)                    every 3 to 5 years; optimize daily PPI therapy

   Indeterminate for          Variable           Optimize acid suppression with TWICE-DAILY
   Dysplasia                                     PPI therapy for 3 to 6 months to resolve active
                                                 inflammation, then REPEAT EGD with biopsies

   Low-Grade Dysplasia        0.5% to 1.4% / yr  1. MUST be confirmed by TWO expert GI pathologists
   (LGD)                                         2. Preferred: Endoscopic Eradication Therapy
                                                    (Radiofrequency Ablation [RFA])
                                                 3. Alternative: Surveillance EGD every 6 to 12 months

   High-Grade Dysplasia       5% to 7% / yr      1. MUST be confirmed by TWO expert GI pathologists
   (HGD)                                         2. Endoscopic Eradication Therapy:
                                                    • Endoscopic Mucosal Resection (EMR) for any
                                                      visible nodules / mucosal irregularities
                                                    • Radiofrequency Ablation (RFA) of remaining
                                                      flat Barrett mucosa
                                                 3. Follow-up surveillance EGD every 3 months
   ═════════════════════════════════════════════════════════════════════════════════════════════

• Endoscopic Eradication Therapy (EET):
  • Radiofrequency Ablation (RFA - Barrx): Delivers controlled thermal energy to a precise mucosal depth (500 to 1,000 micrometers), coagulating the dysplastic metaplastic epithelium down to the muscularis mucosae without damaging the underlying submucosa, allowing healthy squamous epithelium to regenerate under high-dose acid suppression.
  • Endoscopic Mucosal Resection (EMR): Uses suction or band ligation with a snare to excise discrete mucosal nodules or elevated lesions. EMR provides critical full-thickness mucosal histopathology to rule out invasive submucosal (T1b) adenocarcinoma. Any visible lesion in a dysplastic Barrett segment must undergo EMR before applying RFA to the remaining flat segment.
  • Surgical Esophagectomy: Formerly standard for HGD, esophagectomy is now reserved strictly for invasive submucosal adenocarcinoma (T1b or deeper) with lymphovascular invasion, poorly differentiated histology, or lesions refractory to endoscopic ablation.

Dyspepsia: Differential Diagnosis, Rome IV Criteria & Algorithmic Evaluation

Dyspepsia is defined as one or more symptoms referable to the gastroduodenal region: postprandial fullness, early satiety, and epigastric pain or epigastric burning. In primary care, the initial management hinges upon patient age, the presence of alarm signs, and non-invasive Helicobacter pylori testing.

Functional Dyspepsia & Rome IV Diagnostic Criteria

Functional dyspepsia (FD) is diagnosed when symptoms have persisted for at least 3 months, with symptom onset at least 6 months prior, and routine diagnostic evaluation (including EGD) fails to reveal an organic structural etiology. Rome IV subdivides FD into two distinct clinical phenotypes:

1. Postprandial Distress Syndrome (PDS): Characterized by bothersome postprandial fullness (inability to finish a normal-sized meal) and early satiety occurring at least 3 days per week. Pathophysiology involves impaired gastric fundic accommodation and delayed gastric emptying. First-line therapies include dietary modification (small, low-fat, frequent meals) and prokinetic agents (e.g., metoclopramide short-term or buspirone to improve fundic accommodation).
2. Epigastric Pain Syndrome (EPS): Characterized by bothersome, well-localized epigastric pain or burning occurring at least 1 day per week, not exclusively postprandial and not relieved by defecation. First-line medical therapy is an empiric trial of a PPI or H2RA.

                    EVIDENCE-BASED DYSPEPSIA CLINICAL ALGORITHM

   Patient Presents with Uninvestigated Dyspepsia
   (Epigastric pain, burning, postprandial fullness, early satiety)
                               │
               ┌───────────────┴───────────────┐
               ▼                               ▼
   Age >= 60 Years OR Alarm Features   Age < 60 Years AND No Alarm Features
   (Dysphagia, weight loss, bleeding,          │
    vomiting, anemia, family hx)               ▼
               │                       Non-Invasive H. pylori Testing
               ▼                       (Urea Breath Test or Stool Antigen)
   PROMPT UPPER ENDOSCOPY (EGD)                │
   with Gastric Biopsies              ┌────────┴────────┐
                                      ▼                 ▼
                                   POSITIVE          NEGATIVE
                                      │                 │
                                      ▼                 ▼
                              14-Day Bismuth      Empiric PPI Trial
                              Quadruple Therapy   (4 to 8 Weeks)
                              + Confirm Cure            │
                                                        ▼
                                                  If Ineffective:
                                                  Trial Neuromodulator
                                                  (Low-dose TCA e.g.,
                                                   Nortriptyline)

Clinical Management Rules for Dyspepsia

• The Age 60 Threshold: According to the joint ACG/CAG guidelines, the age threshold for performing mandatory initial diagnostic EGD in uninvestigated dyspepsia (without alarm features) is 60 years (reduced from 65 in prior iterations), based on the exponential rise in gastric and esophageal malignancy beyond this age.
• H. pylori Test-and-Treat Strategy: For patients <60 years of age without alarm features, the standard evidence-based strategy is non-invasive H. pylori testing utilizing the urea breath test (UBT) or laboratory-based stool antigen enzyme immunoassay. Serologic antibody testing is strictly obsolete due to poor specificity and inability to distinguish active from cleared infection.
• Pre-Test Washout Rules: Before performing UBT or stool antigen testing, PPIs must be withheld for at least 2 weeks, and antibiotics and bismuth compounds must be withheld for at least 4 weeks to eliminate false-negative results. H2-receptor antagonists and antacids do not interfere with test accuracy.
• Neuromodulators in Refractory Functional Dyspepsia: In patients with functional dyspepsia who fail both H. pylori eradication and high-dose PPI therapy, low-dose tricyclic antidepressants (TCAs), such as nortriptyline (10 to 25 mg at bedtime) or amitriptyline, provide significant symptom relief by blunting visceral hypersensitivity and modulating central pain processing.